Prospects of infusion therapy in the treatment of severe pulmonary tuberculosis in combination with COVID-19
Background. Clinical experience has shown that in conditions of severe quarantine, patients with small respiratory syndromes do not have access to early and quality differential diagnosis. It increases the risk of hospitalization, in such cases, to the infectious department. In most cases, tuberculosis (TB) treatment is no different in people with coronavirus disease (COVID-19).
Objective. Analyze the outlook for the effects of the interaction between COVID-19 and TB, which remains the leading cause of death from a single infectious disease in the world, and for the reduce the risk of TB infection in a pandemic without losing treatment.
Results and discussion. Recently, patients with TB and COVID-19 syntropy, which requires off-label therapy, have to be treated more and more often. This is especially true for patients with diabetes who are at risk for both TB and coronavirus infection. In such cases, which account for approximately 10-15 % of the total, oral therapy (per os) has a high risk of being ineffective. Timely infusion therapy for the synthesis of infectious diseases – TB and COVID-19 – reduces the risk of lethal prognosis. The method of intravenous infusions of anti-TB drugs is the ability to quickly create very high concentrations of drugs in the pulmonary artery, bypassing the liver as the main organ of inactivation and presystemic metabolism. Experience with co-treatment of COVID-19 and TB remains limited. However, suspension of TB treatment in patients with COVID-19 should be exceptional. Prophylactic treatment of TB, treatment of drug-sensitive or resistant TB should be continued continuously to protect the patient’s health, reduce transmission of infection and prevent the development of drug resistance. Therapeutic trials and accumulation of practical experience are underway. However, there are currently no warnings regarding the interaction of drugs used in the treatment of COVID-19 and anti-TB drugs, including the use of infusion therapy in severe conditions.
Conclusions. Timely infusion therapy for the synthesis of infectious diseases – TB and COVID-19 – reduces the risk of lethal prognosis.
This work is licensed under a Creative Commons Attribution 4.0 International License.